Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Apr 17  •  12:09PM ET
25.35
Dollar change
+0.83
Percentage change
3.38
%
Index
RUT
P/E
-
EPS (ttm)
-1.72
Insider Own
3.70%
Shs Outstand
56.32M
Perf Week
9.27%
Market Cap
1.43B
Forward P/E
-
EPS next Y
-0.92
Insider Trans
23.94%
Shs Float
54.30M
Perf Month
-3.13%
Enterprise Value
1.22B
PEG
-
EPS next Q
-0.56
Inst Own
96.69%
Perf Quarter
-16.89%
Income
-95.57M
P/S
4.64
EPS this Y
10.54%
Inst Trans
-0.32%
Perf Half Y
-24.91%
Sales
308.05M
P/B
3.90
EPS next Y
40.05%
ROA
-18.34%
Perf YTD
-19.42%
Book/sh
6.50
P/C
4.99
EPS next 5Y
27.81%
ROE
-24.89%
52W High
66.85 -62.08%
Perf Year
-52.20%
Cash/sh
5.08
P/FCF
-
EPS past 3/5Y
4.30% -7.02%
ROIC
-21.62%
52W Low
19.35 31.01%
Perf 3Y
-31.41%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
60.14% 109.04%
Gross Margin
62.66%
Volatility
4.91% 5.47%
Perf 5Y
-
Dividend TTM
-
EV/Sales
3.97
EPS Y/Y TTM
2.21%
Oper. Margin
-33.71%
ATR (14)
1.49
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
5.77
Sales Y/Y TTM
37.22%
Profit Margin
-31.02%
RSI (14)
51.08
Dividend Gr. 3/5Y
- -
Current Ratio
6.85
EPS Q/Q
-52.00%
SMA20
2.38%
Beta
0.88
Payout
-
Debt/Eq
0.21
Sales Q/Q
11.94%
SMA50
-2.46%
Rel Volume
0.38
Prev Close
24.52
Employees
888
LT Debt/Eq
0.21
SMA200
-27.56%
Avg Volume
1.65M
Price
25.35
IPO
Sep 15, 2021
Option/Short
Yes / Yes
Trades
Volume
271,641
Change
3.38%
Date Action Analyst Rating Change Price Target Change
Mar-06-26Initiated Robert W. Baird Neutral $30
Feb-26-26Downgrade Oppenheimer Outperform → Perform
Feb-26-26Downgrade BofA Securities Neutral → Underperform $20
Dec-12-25Initiated UBS Buy $62
Dec-08-25Downgrade BofA Securities Buy → Neutral $38
Sep-02-25Upgrade Oppenheimer Perform → Outperform $60
Jul-09-25Initiated Stephens Overweight $70
Jul-07-25Initiated Oppenheimer Perform
Dec-02-24Initiated Morgan Stanley Overweight $105
Nov-14-24Initiated Jefferies Hold $95
Apr-09-26 04:05PM
Mar-24-26 11:03AM
Mar-23-26 07:00AM
Mar-16-26 12:27AM
Mar-12-26 09:00AM
08:18AM Loading…
Mar-03-26 08:18AM
Mar-01-26 11:35AM
Feb-26-26 04:34PM
04:06PM
11:21AM
10:17AM
08:30AM
07:55AM
07:04AM
02:11AM
12:04AM Loading…
12:04AM
Feb-25-26 07:25PM
04:02PM
Feb-24-26 10:20AM
Feb-23-26 04:03PM
07:23AM
Feb-12-26 08:09AM
Feb-05-26 08:15AM
Feb-04-26 05:40PM
04:03PM
Jan-26-26 04:03PM
Jan-08-26 09:12AM
Jan-07-26 08:41AM
Dec-22-25 06:50AM
Dec-15-25 07:03AM
04:03PM Loading…
Nov-20-25 04:03PM
Nov-18-25 05:07AM
Nov-05-25 12:04AM
Nov-04-25 05:40PM
04:03PM
Oct-30-25 10:00AM
Oct-29-25 09:00AM
Oct-28-25 10:00AM
Oct-20-25 11:08PM
09:20AM
Oct-15-25 04:03PM
Sep-15-25 09:01AM
Sep-04-25 06:13AM
Aug-27-25 08:29AM
Aug-21-25 12:30PM
11:15AM
Aug-13-25 12:08PM
Aug-06-25 05:45PM
04:03PM
Aug-05-25 08:15AM
Aug-04-25 05:45PM
Jul-31-25 10:30AM
Jul-30-25 10:00AM
Jul-25-25 07:00AM
Jul-24-25 06:00PM
Jul-23-25 08:00AM
Jul-21-25 04:03PM
Jul-14-25 09:15PM
Apr-29-25 04:03PM
Apr-24-25 04:03PM
02:37PM
08:15AM
07:00AM
Apr-10-25 04:03PM
Mar-29-25 06:03PM
Mar-24-25 08:00AM
Mar-20-25 09:05AM
Mar-14-25 08:00AM
Feb-26-25 09:32AM
02:15AM
Feb-25-25 05:25PM
04:02PM
01:22AM
Feb-13-25 02:10PM
Feb-07-25 08:00AM
Jan-16-25 12:00PM
Dec-28-24 04:59AM
Nov-29-24 11:15AM
Nov-26-24 04:05PM
Nov-07-24 12:00PM
Nov-01-24 02:27PM
Oct-29-24 08:43PM
12:00PM
11:56AM
03:03AM
Oct-28-24 05:41PM
04:19PM
02:17PM
11:39AM
08:10AM
07:00AM
07:00AM
Oct-25-24 09:35AM
09:01AM
Oct-21-24 10:00AM
Oct-09-24 04:04PM
Oct-08-24 12:29PM
Oct-07-24 04:04PM
Oct-05-24 06:04PM
Sep-25-24 09:01AM
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nouri AlalehEVP, CLO, CORP. SEC.Mar 19 '26Sale25.965,363139,231105,354Mar 19 05:47 PM
Alalah NouriOfficerMar 19 '26Proposed Sale26.175,363140,349Mar 19 04:57 PM
Nouri AlalehEVP, CLO, CORP. SEC.Mar 17 '26Sale28.153048,559110,717Mar 19 04:25 PM
Waters KevinEVP, CFOMar 17 '26Sale28.1570619,876151,558Mar 19 04:25 PM
Nouri AlalehOfficerMar 17 '26Proposed Sale28.153048,559Mar 17 03:14 PM
Waters KevinOfficerMar 17 '26Proposed Sale28.1570619,876Mar 17 03:13 PM
Nouri AlalehEVP, CLO, CORP. SEC.Mar 10 '26Sale25.653,24383,197111,021Mar 12 04:02 PM
Alalah NouriOfficerMar 10 '26Proposed Sale25.263,24381,918Mar 10 04:04 PM
Desai Antal RohitDirectorMar 05 '26Buy25.58167,2464,278,549167,246Mar 09 07:19 PM
Desai Antal RohitDirectorMar 06 '26Buy23.59160,3173,781,503327,563Mar 09 07:19 PM
Desai Antal RohitDirectorMar 09 '26Buy24.5598,6992,422,891426,262Mar 09 07:19 PM
Nouri AlalehEVP, CLO, CORP. SEC.Mar 06 '26Sale23.706,892163,353114,264Mar 09 05:43 PM
Waters KevinEVP, CFOMar 06 '26Sale23.706,721159,300152,264Mar 09 05:40 PM
Nouri AlalehOfficerMar 06 '26Proposed Sale23.706,892163,353Mar 06 04:19 PM
Waters KevinOfficerMar 06 '26Proposed Sale23.706,721159,300Mar 06 04:07 PM
Desai Antal RohitDirectorAug 14 '25Option Exercise1.3326,74935,57635,152Aug 15 04:53 PM
MOLL FREDERIC HDirectorAug 13 '25Buy39.2620,000785,138863,159Aug 14 04:18 PM
Nouri AlalehEVP, CLO, CORP. SEC.Aug 14 '25Option Exercise4.5211,00049,72072,473Aug 14 04:15 PM
Desai Antal RohitDirectorJun 10 '25Sale63.9125,0001,597,71164,363Jun 12 07:28 PM
Desai Antal RohitDirectorJun 11 '25Sale63.3825,0001,584,52539,363Jun 12 07:28 PM
Desai Antal RohitDirectorJun 12 '25Sale61.4925,0001,537,25614,363Jun 12 07:28 PM
SHAM SHIBLAQOfficerJun 06 '25Proposed Sale64.1320,0001,282,638Jun 06 04:22 PM
Shiblaq HishamEVP, Chief Comm. OfficerJun 06 '25Option Exercise5.1820,000103,60083,133Jun 06 04:02 PM
Shiblaq HishamEVP, Chief Comm. OfficerJun 06 '25Sale64.1320,0001,282,63763,133Jun 06 04:02 PM
Desai Antal RohitDirectorJun 05 '25Sale64.7925,0001,619,83089,363Jun 05 08:05 PM
Desai Antal RohitDirectorJun 04 '25Sale61.0225,0001,525,556114,363Jun 05 08:05 PM
Desai Antal RohitDirectorJun 03 '25Sale60.6625,0001,516,475139,363Jun 05 08:05 PM
222 DNA TRUST DirectorJun 03 '25Proposed Sale57.94150,0008,691,000Jun 03 04:24 PM
Zadno RezaPresident, CEOMay 09 '25Option Exercise7.2713,759100,028186,829May 13 04:59 PM